Simplify Logo

Full-Time

Senior Scientist II

Analytical Development

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Hardware
Biotechnology
Healthcare

Compensation Overview

$160k - $200kAnnually

+ Equity Awards + Benefits + Learning and Development Opportunities

Senior, Expert

San Carlos, CA, USA

Category
Lab & Research
Life Sciences
Required Skills
Communications
Quality Assurance (QA)
Requirements
  • Master’s degree with 10+ years or PhD with 8+ years of relevant industrial experience in analytical development.
  • Extensive experience leading analytical activities independently in small molecule drug development.
  • Experience managing projects at CROs/CDMOs.
  • Work experience and knowledge of regulatory submission (IND, IMPD, and / or NDA).
  • Effective written and verbal communication skills and interpersonal skills.
  • Extensive knowledge and understanding of current ICH guidelines, GMP guidelines, and related industry practices.
  • Strong problem-solving skills with sound technically driven decision-making ability.
  • Excellent scientific and business communication skills (verbal, written and technical), strong interpersonal/collaboration skills and planning skills.
  • Ability to think critically and creatively and be able to work independently to determine appropriate resources for resolution of problems.
  • Ability to multi-task and thrive in a fast-paced innovative environment.
Responsibilities
  • Lead day-to-day operations to provide analytical support for API process R&D and manufacturing, formulation development and drug product manufacturing, and participate in cross-functional project team meetings.
  • Contribute to analytical development strategy for multiple projects.
  • Demonstrate technical expertise on analytical technologies and act as a subject matter expert for Analytical Development function.
  • Select appropriate analytical techniques and coach and/or manage the contract lab counterparts to perform analytical method development/validation/transfer to support development and manufacturing of API and drug product.
  • Critically review data from contract partners (CDMOs and/or CTLs).
  • Manage stability testing programs assigned.
  • Prepare, review, and/or approve study protocols, study reports, and CMC regulatory submission document.
  • Collaborate with cross functional teams including but not limited to Medicinal Chemistry, DMPK, Toxicology, QA, Pharmaceutical Development, Process R&D, Project Management and Regulatory to timely achieve project goals.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to inhibit the activity of RAS proteins that promote cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses specifically on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$1.3B

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

40%

2 year growth

111%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.